About
Professional SummaryDr. Raja Solomon Viswas was born in Aruppukottai, India. He received his bachelor’s degree in Pharmacy from the S. B. College of Pharmacy, the Tamilnadu Dr. M. G. R. Medical University, Chennai, India, and master’s degree in Pharmacy with specialization of Medicinal & Pharmaceutical chemistry from the S. G. S. Institute of Technology, the Rajiv Gandhi Technical University, Bhopal, India, under the direction of Prof. S. C. Chaturvedi. He completed his Ph.D. in the field of Medicinal Chemistry at the CSIR-Central Drug Research Institute (CDRI), Lucknow, India, under the guidance of Prof. S. B. Katti and then moved to Advanced Medical Research Institute of Canada/Health Science North, as an Ontario Government of Ministry of Research innovation postdoctoral fellow in the Prof. Hoyun Lee research group. He is presently working as a Research Scientist at the Dept of Medical Imaging at the University of Saskatchewan, Saskatoon with Prof. Humphrey Fonge. His research interests include (i) development of novel immune-SPECT/PET agents for cancer; (ii) development of novel targeted alpha therapy (TAT) agents for colorectal and breast cancer treatment (iii) design, synthesis, and biological evaluation of hybrid molecules for cancer drug discovery; and (iv) development of new synthetic methodologies for application in organic and bifunctional chelators synthesis.
Education
Academic Background-
Ph.D. Dr. Bhim Rao Ambedkar Open University Agra, India Chemistry | Completed: 2006
-
M.Sc. Rajiv Gandhi Prodyogiki, Vishvavidyalaya, Bhopal, India Pharmacy | Completed: 2002
-
B.Sc. The Tamil Nadu Dr. Maruthur Gopalan Ramachandran Medical University, Chennai, India Pharmacy | Completed: 1999
Editorial Services
Editorial & Publishing Roles
Editorial Board Member
Serving as Editorial Board Member for International Journal of Biological Chemistry.
Editorial Board Member
Serving as Editorial Board Member for Asian Journal of Scientific Research.
Editorial Board Member
Serving as Editorial Board Member for Journal of Pharmacy and Allied Health Sciences.
Publications (87)
Selected Scholarly Contributions
Correction: Ajith et al. Recent Developments in Electrospun Nanofibers as Delivery of Phytoconstituents for Wound Healing. Drugs Drug Candidates 2023, 2, 148–171
2026
Innovative Approaches to Alzheimer's Treatment: Utilizing Tacrine Hybrids to Inhibit Amyloid Beta Aggregation as a Strategic Focus
2026
Synergistic Liposomal Delivery of Ibrexafungerp Citrate and Marine-Sourced Silver Nanoparticles for Effective Management of Vulvovaginal Candidiasis
2026
Optimizing processes and unveiling the therapeutic potential of electrospun gelatin nanofibers for biomedical applications
2025
Unveiling the mTOR pathway modulation by SGLT2 inhibitors: a novel approach to Alzheimer’s disease in type 2 diabetes
2025
A New Class of BRCA1 Mimetics for ERα-Positive Breast Cancer Therapy: Design, Synthesis, In Silico Screening, In Vitro Assay, and Gene Expression Analysis
2025
State-of-the-art supercritical fluid techniques for nanosponge engineering: An in-depth review of advances and clinical impact
2025
Advancements and Challenges in 3D Printing for Wound Healing: Current Trends and Future Prospects
2025
Investigating the potential of Commelina benghalensis Linn. in breast cancer treatment: Insights from network pharmacology, molecular docking, and dynamic simulations
2025
Liquid chromatography–tandem mass spectrometry determination of bumetanide in human plasma and application to a clinical pharmacokinetic study
2024
Fabrication of Quercetin-Functionalized Morpholine and Pyridine Motifs-Laden Silk Fibroin Nanofibers for Effective Wound Healing in Preclinical Study
2024
Molecular docking and molecular dynamics simulations discover curcumin analogs as potential wound healing agents
2024
Synergic Effects of Ordered Mesoporous Bifunctional Ionic Liquid: A Recyclable Catalyst to Access Chemoselective N-Protected Indoline-2,3-dione Analogous
2024
Advances in electrospun chitosan nanofiber biomaterials for biomedical applications
2023
Recent Developments in Electrospun Nanofibers as Delivery of Phytoconstituents for Wound Healing
2023
Recent Trends in Electrospun Antibacterial Nanofibers for Chronic Wound Management
2023
Recent Advances in Silver Nanoparticles Containing Nanofibers for Chronic Wound Management
2022
Emerging trends in curcumin embedded electrospun nanofibers for impaired diabetic wound healing.
Viswas Raja Solomon
2022
Design, synthesis, and structure-activity relationships of novel 1-(substituted)-2-methyl-3-(4-oxo-2-methylquinazolin-3(4h)-yl) isothioureas for their anti-hiv and antibacterial activities.
Viswas Raja Solomon
2022
89Zr-Labeled Domain II-Specific scFv-Fc ImmunoPET Probe for Imaging Epidermal Growth Factor Receptor In Vivo
2021
Anti-HIV and antibacterial activities of novel 2-(3-substituted-4-oxo-3,4-dihydroquinazolin-2-yl)-2,3-dihydrophthalazine-1,4-diones.
Viswas Raja Solomon
2021
Nimotuzumab Site-Specifically Labeled with 89Zr and 225Ac Using SpyTag/SpyCatcher for PET Imaging and Alpha Particle Radioimmunotherapy of Epidermal Growth Factor Receptor Positive Cancers
2020
Design and synthesis of 1-substituted-4-(4-Nitrophenyl)-[1,2,4]triazolo[4,3-a]quinazolin-5(4H)-ones as a new class of antihistaminic agents.
Viswas Raja Solomon
2020
Preclinical evaluation of 111In-Labeled PEGylated maytansine nimotuzumab drug conjugates in EGFR-positive cancer models.
Viswas Raja Solomon
2019
GABA allosteric modulators: An overview of recent developments in non-benzodiazepine modulators.
Viswas Raja Solomon
2019
111In- and 225Ac-labeled cixutumumab for imaging and α-particle radiotherapy of IGF-1R positive triple-negative breast cancer.
Viswas Raja Solomon
2019
89Zr-nimotuzumab for immunoPET imaging of epidermal growth factor receptor I.
Viswas Raja Solomon
2018
99mTc(CO)3+ labeled domain I/II-specific anti-EGFR (scFv)2 antibody fragment for imaging EGFR expression.
Viswas Raja Solomon
2018
A 89Zr-labeled lipoplex nanosystem for image-guided gene delivery: design, evaluation of stability and in vivo behavior.
Viswas Raja Solomon
2018
Exploring the binding of barbital to a synthetic macrocyclic receptor. A charge density study.
Viswas Raja Solomon
2018
An overview of quinazolines: Pharmacological significance and recent developments.
Viswas Raja Solomon
2018
Design and synthesis of novel quinacrine-[1,3]-thiazinan-4-one hybrids for their anti-breast cancer activity.
Viswas Raja Solomon
2017
Design, synthesis and characterization of novel quinacrine analogs that preferentially kill cancer over non-cancer cells through the down-regulation of Bcl-2 and up-regulation of bax and bad.
Viswas Raja Solomon
2017
Identification of SNAIL1 peptide-based irreversible lysine-specific demethylase 1-selective inactivators.
Viswas Raja Solomon
2015
VR23: a quinoline-sulfonyl hybrid proteasome inhibitor that selectively kills cancer via cyclin e-mediated centrosome amplification.
Viswas Raja Solomon
2015
The potential of quinoline derivatives for the treatment of Toxoplasma gondii infection.
Viswas Raja Solomon
2014
Design and synthesis of 3-(4-chlorophenyl)-2-(2-(4-substituted)-2-oxoethylthio) quinazolin-4 (3H)-one as antihistamine agents.
Viswas Raja Solomon
2014
2,3-disubtituted thiazolidin-4-ones: Novel class of anticonvulsant agents.
Viswas Raja Solomon
2012
Synthesis and antibacterial activity of some novel 1-(4-oxo-3-(3-methoxyphenyl)-3H-quinazolin-2-yl)-4-(substituted) thiosemicarbazides.
Viswas Raja Solomon
2012
Anti-breast cancer activity of heteroaryl chalcone derivatives.
Viswas Raja Solomon
2012
Design, synthesis and biological evaluation of some novel 3-cinnamoyl-4-hydroxy-2H-chromen-2-ones as antimalarial agents.
Viswas Raja Solomon
2012
Synthesis of some coumarinyl chalcones and their antiproliferative activity against breast cancer cell lines.
Viswas Raja Solomon
2011
Synthesis and Analgesic, Anti-inflammatory Activities of 3-(3-Methoxyphenyl)-2-Substituted amino-quinazolin-4(3H)-ones.
Viswas Raja Solomon
2011
Quinoline is a privileged scaffold for cancer drug discovery.
Viswas Raja Solomon
2011
Design and synthesis of chloroquine analogs for their anti-breast cancer property.
Viswas Raja Solomon
2010
A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells.
Viswas Raja Solomon
2010
Design and synthesis of CQ analogs for their anti-breast cancer property.
Viswas Raja Solomon
2010
4-Aminoquinoline derived antimalarials: Synthesis and heme polymerization inhibition studies.
Viswas Raja Solomon
2010
Design and synthesis of anti-breast cancer agents from 4-piperazinylquinoline: A hybrid pharmacophore approach.
Viswas Raja Solomon
2010
Synthesis and pharmacological evaluation of 3-cyclohexyl-2-substituted amino-3H-quinazolin-4-ones as analgesic and anti-inflammatory agent.
Viswas Raja Solomon
2009
Topological descriptors in modelling antimalarial activity: N1-(7-chloro-4-quinolyl)-1,4-bis(3-aminopropyl)piperazine as prototype.
Viswas Raja Solomon
2009
4-(3-Methoxyphenyl)-1-substituted-4H-[1,2,4]triazolo[4,3-a] quinazolin-5-ones: New class of H1-Antihistaminic agents veerachamy alagarsamy.
Viswas Raja Solomon
2009
Synthesis of 3-(3-Ethylphenyl)-2-substituted amino-3H-quinazolin-4-ones as novel class of Analgesic and Anti-inflammatory agents.
Viswas Raja Solomon
2009
Synthesis and pharmacological investigation of novel 4-(3-ethylphenyl)-1-substituted-4H-[1,2,4]triazolo[4,3-a] quinazolin-5-ones as new class of H1-antihistaminic agents.
Viswas Raja Solomon
2009
Hybrid pharmacophore design and synthesis of isatin-benzothiazole analogs for their anti-breast cancer activity.
Viswas Raja Solomon
2009
Chloroquine and its analogs: A new promise of an old drug for effective and safe cancer therapies.
Viswas Raja Solomon
2009
Synthesis and antimalarial activity of novel side chain modified antimalarial agents from 4-aminoquinoline.
Viswas Raja Solomon
2008
Synthesis of 3-(2-pyridyl)-2-Substituted-quinazolin-4(3H)-ones as new analgesic and Anti-inflammatory agents.
Viswas Raja Solomon
2008
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
Viswas Raja Solomon
2008
Synthesis, analgesic, anti-inflammatory and ulcerogenic index activities of novel 2-methylthio-3-substituted-5,6-dimethyl thieno [2,3-d] pyrimidin-4(3H)-ones.
Viswas Raja Solomon
2008
Design and synthesis of 3-(4-Ethylphenyl)-2-substitutedamino-3H-quinazolin-4-ones as novel class of analgesic and Anti-inflammatory agents.
Viswas Raja Solomon
2008
Synthesis and pharmacological evaluation of some 3-(2-Methylphenyl)-2-Substituted amino-quinazolin-4(3H)-ones as analgesic and Anti-inflammatory agents.
Viswas Raja Solomon
2008
Synthesis and pharmacological investigation of novel 4-(4-ethyl phenyl)-1-substituted-4H-[1,2,4]triazolo[4,3-a] quinazolin-5-ones as new class of H1-antihistaminic agents.
Viswas Raja Solomon
2008
Synthesis and in vitro cytotoxicity evaluation of 4-aminoquinoline derivatives.
Viswas Raja Solomon
2008
Synthesis and pharmacological evaluation of some 3-phenyl-2-substituted-3H-quinazolin-4-ones as analgesic, anti-inflammatory agents.
Viswas Raja Solomon
2007
Synthesis of 2-Mercapto-3-substituted-5,6-dimethylthieno[2,3-d] pyrimidin-4(3H)-ones as new analgesic, Anti-inflammatory agents.
Viswas Raja Solomon
2007
Synthesis and pharmacological investigation of novel 4-benzyl-1-substituted-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-ones as new class of H1-antihistaminic agents.
Viswas Raja Solomon
2007
Synthesis of novel 3-Butyl-2-Substituted Amino-3H-Quinazolin-4-ones as analgesic and Anti-inflammatory agents.
Viswas Raja Solomon
2007
Synthesis and pharmacological investigation of 3-Subsituted-amino-2-methylsulfanyl-5,6,7,8-tetrahydro-3H-benzo[4,5]thieno[2,3-d]pyrimidin-4-ones as analgesic and Anti-Inflammatory agents.
Viswas Raja Solomon
2007
4-Cyclohexyl-1-substituted-4H-[1,2,4]triazolo [4,3-a] quinazolin-5-ones: Novel Class of H1-antihistaminic agents.
Viswas Raja Solomon
2007
Design and synthesis of 2-Methylthio-3-substituted-5,6-dimethylthieno [2,3-d] pyrimidin-4(3H)-ones as analgesic Anti-Inflammatory and antibacterial agents.
Viswas Raja Solomon
2007
Synthesis and antimalarial activity of side chain modified 4-aminoquinoline derivatives.
Viswas Raja Solomon
2007
Design, synthesis and antimalarial activity of a new class of iron chelators.
Viswas Raja Solomon
2006
Synthesis, analgesic, anti-inflammatory, ulcerogenic index and antibacterial activities of novel 2-methylthio-3-substituted-5,6,7,8-tetrahydrobenzo (b) thieno[2,3-d]pyrimidin-4(3H)-ones.
Viswas Raja Solomon
2006
Synthesis of some novel 2-Mercapto-3-(substituted amino)-5,6,7,8-tetrahydro-3H-benzo[4,5]thieno[2,3-d]pyrimidin-4-ones as analgesic and Anti-inflammatory agents.
Viswas Raja Solomon
2006
Synthesis, analgesic, Anti-inflammatory and antibacterial activities of some novel 2-Butyl-3-subtituted Quinazolin-4(3H)-ones.
Viswas Raja Solomon
2005
Topological descriptors in modeling the HIV-RT inhibitory activityof 2-aryl-3-pyridyl-thiazolidin-4-one.
Viswas Raja Solomon
2005
Synthesis and QSAR studies on thiazolidinones as HIV-RT inhibitors.
Viswas Raja Solomon
2005
Design and synthesis of new antimalarial agents from 4-aminoquinoline.
Viswas Raja Solomon
2005
Anticancer, antibacterial and antifungal activites of some 2-substituted (1,3,4) thiadiazolo (2,3-b) tetrahydrobenzo (b) thieno (3,2-e) pyrimidines.
Viswas Raja Solomon
2004
QSAR Studies of diphenylpropionic acids based selective AT1 angiotensin II receptor antagonist as antihypertensive agents.
Viswas Raja Solomon
2004
CP-MLR/PLS directed structure activtity molecular modeling of the HIV-1 RT inhibitory activity of 2,3-Diaryl-1,3-thiazolidin-4-ones.
Viswas Raja Solomon
2004
Analysis of a series of new pyrazolidine-3,5-diones as selective AT1 angiotensin Ii receptor antagonists.
Viswas Raja Solomon
2003
Anti HIV and antibacterial activites of 2-substituted thiadiazolo quinazolines.
Viswas Raja Solomon
2003
Anti HIV and antibacterial activites of 2-Subtituted thiadiazolo quinazolines.
Viswas Raja Solomon
2003
Synthesis, analgesic, Anti-inflammatory and antibacterial activities of some novel 2-Phenyl-3-subtituted Quinazolin-4(3H)-ones.
Viswas Raja Solomon
2002
Angiotensin antagonist: As antihypertensive agents.
Viswas Raja Solomon
2002